Skip to main content

U of A research supports reports of Merck pill efficacy


An Edmonton-tested antiviral pill that is said to cut COVID-19 hospitalizations and deaths in half is now being reviewed by Health Canada.

The drug was studied at the University of Alberta (U of A) and, if approved, will become the first oral pill proven to treat COVID-19.

U of A researchers say, while vaccines are the best tool for preventing severe disease, there's now potentially an option for oral treatment of COVID-19 infections as well.

Molnupiravir was originally created to fight Influenza, but initial studies have shown success in fighting COVID-19 infections.

Researchers at the U of A told CTV News Edmonton they believe they understand how the drug works. Their research was published in the Journal of Biological Chemistry. 

"The drug causes the virus to make too many mistakes," said Dr. Matthias Gotte, a professor teaching at the U of A's medical microbiology and immunology department.

"The genome replicates in a very sloppy way so that the viruses that are newly generated, they are not infectious anymore and this is what we have shown with biochemical experiments."

According to Merck, molnupiravir should be taken eight times a day within five days of first experiencing COVID-19 symptoms.

Canada's chief medical adviser said a review of the drug is underway, but testing could take months, and the pill will only be approved if it works well and is safe.

"I was extremely happy. This is exactly what we need right now," said Dr. Gotte.

Merck says it plans to submit the drug for approval in the United States and other countries in the coming days. Top Stories

How the $68 million Gold Draw jackpot got up to its maximum

A winning lottery ticket always comes with some sort of prize, but this month it was revealed that not only had the Lotto 6/49 jackpot reached $68 million for the first time in history, but that it was guaranteed to go to the next winning ticket. Here’s how that happened.

Stay Connected